Intuitive Surgical stock remains in focus after Q1 2026 Revenue rose to $2.77 billion, da Vinci procedure growth accelerated and operating margins expanded on strong robotic surgery Demand.

Key Highlights

  • Intuitive Surgical reported 23% year-over-year revenue growth in Q1 2026.
  • da Vinci procedures increased 16% while Ion procedures rose 39%.
  • Operating margins expanded to 39% as da Vinci 5 adoption accelerated.

Intuitive Surgical, Inc. (Nasdaq: ISRG) is one of the most-watched US large-cap medical device stocks. With a market Capitalization of about $149.15 billion, ISRG continues to lead the robotic surgery sector. Shares fell 1.62%.

Why the Stock Is in Focus Today

Intuitive Surgical Q1 2026 revenue rose 23% year over year to $2.77 billion, beating the $2.62 billion consensus by 6%. da Vinci procedures grew 16% to approximately 847,000 cases and Ion procedures surged 39% to about 43,000 cases. Operating Income of $1.08 billion jumped 40% year over year, with EBIT margins expanding to 39% from 34%. Management raised 2026 da Vinci procedure growth guidance to 13.5-15.5%.

da Vinci 5 contribution margins reached Parity with the legacy Xi system in the quarter, and the company estimates a 160,000-procedure cardiac robotics opportunity for the platform.

Latest Share Price Movement

ISRG traded at $421.12, down 1.62% on the day, with Volume of 2.37 million shares and a relative volume reading of 1.04. Coverage from Yahoo Finance noted the stock revisited support near $430-$458 on May 11, with year-to-date performance down approximately 23.7%.

Key News Driving Investor Attention

Three news items dominate. First, the Q1 beat. Second, the da Vinci 5 contribution Margin parity with Xi. Third, the procedure guidance raise.

Earnings and Financial Performance

Diluted EPS on a trailing-twelve-month basis stands at $8.24 with EPS growth of +20.92% year over year. The 2026 EPS estimate has moved up 15.2% over the past year to $10.40.

Sector Outlook

Intuitive Surgical competes in robotic surgery with Medtronic Hugo, Johnson &Amp; Johnson Ottava and Asensus. The da Vinci platform's installed base remains the deepest in the industry.

Risks Investors Are Watching

Risks include hospital capex sensitivity, competitive entry from Medtronic and J&J, da Vinci 5 ramp execution and procedure growth normalization in mature US markets.

What to Watch Next

Catalysts ahead include Q2 2026 results, da Vinci 5 cardiac procedure ramp and international procedure expansion.

Conclusion

Intuitive Surgical continues to strengthen its Leadership position within robotic-assisted surgery through expanding procedure volumes, improving platform Economics and accelerating adoption of the da Vinci 5 system. The company’s margin expansion and guidance increase suggest sustained procedural demand despite broader hospital spending concerns. However, investors remain attentive to competitive developments, healthcare Capital Expenditure trends and the pace of international expansion. Future results may provide greater clarity on whether next-generation robotic platforms can support another phase of Long-term Growth.